Literature DB >> 1640712

Prognostic profile for patients with pheochromocytoma derived from clinical and pathological factors and DNA ploidy pattern.

O Nativ1, C S Grant, S G Sheps, J R O'Fallon, G M Farrow, J A van Heerden, M M Lieber.   

Abstract

Eighty-eight patients with pheochromocytoma and paraganglioma treated over a 28 year period (1960-1987) were studied. Based on clinical course, they were divided into three prognostic groups: benign (n = 57); multiple (n = 12); and metastatic (n = 19). Using clinical data, histopathologic findings, and tumor nuclear DNA content a prognostic profile for each group was constructed. The following variables were studied: age, familial pheochromocytoma, associated endocrine or neoplastic disorders, number and location of the lesion at diagnosis, size of the tumor, and the nuclear DNA ploidy pattern. Of these prognostic factors the most significant to predict a future malignant clinical course were large size and local tumor extension at time of surgery. Family history of pheochromocytoma, associated endocrine disorders, and young age at presentation predicted multiplicity. Old age, absence of familial pheochromocytoma or related endocrine disorders and DNA diploid tumors seem to be favorable findings. Using these variables in combination may be helpful for early identification of patients with malignant, multiple, or benign pheochromocytoma and paraganglioma.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1640712     DOI: 10.1002/jso.2930500413

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  6 in total

Review 1.  Malignant pheochromocytomas and paragangliomas: a diagnostic challenge.

Authors:  Oliver Gimm; Catherine DeMicco; Aurel Perren; Francesco Giammarile; Martin K Walz; Laurent Brunaud
Journal:  Langenbecks Arch Surg       Date:  2011-11-29       Impact factor: 3.445

2.  Leu-M1 immunoreactivity and phaeochromocytoma.

Authors:  L Masmiquel; M Castro-Forns; I de Torres; A García; M T Vidal; R Simó
Journal:  J Clin Pathol       Date:  1997-02       Impact factor: 3.411

3.  Size of the tumor and pheochromocytoma of the adrenal gland scaled score (PASS): can they predict malignancy?

Authors:  Amit Agarwal; Prateek K Mehrotra; Manoj Jain; Sushil K Gupta; Anjali Mishra; Gyan Chand; Gaurav Agarwal; A K Verma; S K Mishra; Uttam Singh
Journal:  World J Surg       Date:  2010-12       Impact factor: 3.352

4.  Composite Pheochromocytoma-Ganglioneuroma of the Adrenal Gland: An Uncommon Entity with Distinctive Clinicopathologic Features.

Authors:  King-Yin Lam; Chung-Yau Lo
Journal:  Endocr Pathol       Date:  1999       Impact factor: 3.943

Review 5.  Laparoscopic surgery for malignant adrenal tumors.

Authors:  G N Zografos; G Vasiliadis; A N Farfaras; C Aggeli; M Digalakis
Journal:  JSLS       Date:  2009 Apr-Jun       Impact factor: 2.172

6.  Pheochromocytoma.

Authors:  Lee C Pederson; Jeffrey E Lee
Journal:  Curr Treat Options Oncol       Date:  2003-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.